ProBioGen

Executive Summary

ProBioGen AG is a German CDMO and technology provider with over 30 years of experience in developing and manufacturing biopharmaceuticals, including proteins, antibodies, viral vectors, and vaccines. The company leverages proprietary technologies such as its CHO cell line platforms and viral vector production systems to enhance product quality and yield, positioning itself as a high-quality partner for biotech and pharma companies. As the biologics market expands, particularly in gene and cell therapy, ProBioGen is well-positioned to capitalize on growing demand for viral vector manufacturing. However, the CDMO space is increasingly competitive, and ProBioGen’s ability to scale capacity and secure long-term contracts will be key to its growth. The company’s private status and German base provide stability but limit visibility into near-term financial performance.

Upcoming Catalysts (preview)

• Q1 2027Announcement of new manufacturing capacity expansion70% success
• Q4 2026Major partnership or long-term supply agreement with a biotech firm60% success
• Q3 2026Milestone in proprietary viral vector platform (e.g., yield improvement data)50% success